Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Receivables (2022 - 2025)

Coeptis Therapeutics Holdings (COEP) has 4 years of Receivables data on record, last reported at $86041.0 in Q3 2025.

  • For Q3 2025, Receivables changed N/A year-over-year to $86041.0; the TTM value through Sep 2025 reached $86041.0, changed N/A, while the annual FY2023 figure was $38978.0, 382.7% up from the prior year.
  • Receivables reached $86041.0 in Q3 2025 per COEP's latest filing, up from $30000.0 in the prior quarter.
  • Across five years, Receivables topped out at $108581.0 in Q1 2024 and bottomed at $833.0 in Q3 2023.
  • Average Receivables over 4 years is $45418.0, with a median of $34489.0 recorded in 2023.
  • The widest YoY moves for Receivables: up 382.7% in 2023, down 382.7% in 2023.
  • A 4-year view of Receivables shows it stood at $8075.0 in 2022, then soared by 382.7% to $38978.0 in 2023, then soared by 178.57% to $108581.0 in 2024, then dropped by 20.76% to $86041.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $86041.0 in Q3 2025, $30000.0 in Q2 2025, and $108581.0 in Q1 2024.